Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update

doi:10.1111/hepr.13503

Record: found
Abstract: not found
Article: not found

Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update

Author(s): Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology

Publication date (Electronic): May 29 2020

Journal: Hepatology Research

Publisher: Wiley

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 80

Record: found
Abstract: found
Article: not found

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

David Roth, David R. Nelson, Annette Bruchfeld … (2015)

Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.

0 comments Cited 186 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Stefan Zeuzem, Graham R. Foster, Stanley Wang … (2018)

0 comments Cited 147 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

María Elisa Reig, Zoe Mariño, Christie Perelló … (2016)

The success of direct-acting antivirals (DAA) against hepatitis C is a major breakthrough in hepatology. Until now, however, there are very few data on the effect of hepatitis C virus (HCV) eradication in patients who have already developed hepatocellular carcinoma.

0 comments Cited 147 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: Hepatology Research

Abbreviated Title: Hepatol Res

Publisher: Wiley

ISSN (Print): 1386-6346

ISSN (Electronic): 1872-034X

Publication date Created: July 2020

Publication date (Electronic): May 29 2020

Publication date (Print): July 2020

Volume: 50

Issue: 7

Pages: 791-816

Article

DOI: 10.1111/hepr.13503

PubMed ID: 32343477

SO-VID: 9bafc714-46e1-4bef-9665-11ce65b08a19

License:

http://onlinelibrary.wiley.com/termsAndConditions#vor

http://doi.wiley.com/10.1002/tdm_license_1.1

History

ScienceOpen disciplines: Quantitative & Systems biology,Biophysics

Data availability:

ScienceOpen disciplines: Quantitative & Systems biology, Biophysics

Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update

Read this article at

Related collections

iGEM

Most cited references 80

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Author and article information

Journal

Article

History

Comments

Comment on this article

Similar content 1,157

Cited by 31

Most referenced authors 1,450